Secukinumab: A life-changing treatment for Netherton syndrome?

Ann Dermatol Venereol. 2023 Mar;150(1):61-63. doi: 10.1016/j.annder.2022.08.005. Epub 2022 Nov 22.

Authors

Jerome Kaikati¹, Reine Merhy², Anne-Sophie Sarkis², Roland Tomb²

Affiliations

¹ Department of Dermatology, Hôtel Dieu de France Hospital, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon. Electronic address: [email protected].
² Department of Dermatology, Hôtel Dieu de France Hospital, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.

PMID: 36428119
DOI: 10.1016/j.annder.2022.08.005

No abstract available

Keywords: IL-17 inhibitor; Netherton syndrome; Secukinumab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Netherton Syndrome*
Phenotype
Treatment Outcome

Substances

secukinumab
Antibodies, Monoclonal, Humanized